{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T01:56:15Z","timestamp":1769738175239,"version":"3.49.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.semcancer.2015.08.006","type":"journal-article","created":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T23:13:52Z","timestamp":1440198832000},"page":"125-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches"],"prefix":"10.1016","volume":"35","author":[{"given":"Petros D.","family":"Grivas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilena","family":"Melas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios G.","family":"Papavassiliou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2015.08.006_bib0345","first-page":"259","article-title":"Molecular pathogenesis of urothelial bladder cancer","volume":"18","author":"Theodorescu","year":"2003","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0350","series-title":"SEER Data","author":"National Cancer Institute","year":"2015"},{"key":"10.1016\/j.semcancer.2015.08.006_bib0355","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev."},{"issue":"5","key":"10.1016\/j.semcancer.2015.08.006_bib0360","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1080\/02841860902913546","article-title":"Occupation and cancer \u2013 follow-up of 15 million people in five Nordic countries","volume":"48","author":"Pukkala","year":"2009","journal-title":"Acta Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2015.08.006_bib0365","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bcp.12306","article-title":"Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis","volume":"78","author":"Turner","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.semcancer.2015.08.006_bib0370","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00125-014-3456-9","article-title":"Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis","volume":"58","author":"Levin","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.semcancer.2015.08.006_bib0375","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.urology.2005.08.064","article-title":"Bladder tumor markers beyond cytology: International Consensus panel on bladder tumor markers","volume":"66","author":"Lokeshwar","year":"2005","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.semcancer.2015.08.006_bib0380","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/ng.907","article-title":"Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder","volume":"43","author":"Gui","year":"2011","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.semcancer.2015.08.006_bib0385","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/ng.2798","article-title":"Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation","volume":"45","author":"Guo","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0390","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Weinstein","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.semcancer.2015.08.006_bib0395","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.urolonc.2010.04.008","article-title":"Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression","volume":"28","author":"McConkey","year":"2010","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0400","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/0970-1591.38606","article-title":"Molecular markers in transitional cell carcinoma of the bladder: new insights into mechanisms and prognosis","volume":"24","author":"Ehdaie","year":"2008","journal-title":"Indian J. Urol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0405","doi-asserted-by":"crossref","first-page":"429213","DOI":"10.1155\/2012\/429213","article-title":"A decade of FGF receptor research in bladder cancer: past, present and future challenges","volume":"2012","author":"Di Martino","year":"2012","journal-title":"Adv. Urol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0410","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/carcin\/bgi290","article-title":"Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b","volume":"27","author":"Bernard-Pierrot","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.semcancer.2015.08.006_bib0415","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/300762a0","article-title":"Activation of the T24 bladder carcinoma transforming gene in linked to a single amino acid change","volume":"300","author":"Taparowsky","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2015.08.006_bib0420","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.humpath.2011.10.026","article-title":"Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer","volume":"43","author":"Juanpere","year":"2012","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0425","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2012.46.5740","article-title":"Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer","volume":"31","author":"Iyer","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0430","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/modpathol.2013.135","article-title":"Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy","volume":"27","author":"Ross","year":"2014","journal-title":"Mod. Pathol."},{"issue":"16","key":"10.1016\/j.semcancer.2015.08.006_bib0435","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","article-title":"Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial","volume":"25","author":"Hussain","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.semcancer.2015.08.006_bib0440","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1002\/cncr.28767","article-title":"A randomized phase 2 trial of gemcitabine\/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma","volume":"120","author":"Hussain","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2015.08.006_bib0445","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0450","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2015.08.006_bib0455","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/path.2892","article-title":"Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma","volume":"224","author":"Al-Ahmadie","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0460","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/blood-2005-12-5148","article-title":"Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia","volume":"108","author":"Kojima","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2015.08.006_bib0465","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0470","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ajpath.2013.05.013","article-title":"Toward a molecular pathologic classification of urothelial carcinoma","volume":"183","author":"Sjodahl","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0475","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/path.4017","article-title":"CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma","volume":"227","author":"Rebouissou","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0480","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0485","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"Suppl. 7","key":"10.1016\/j.semcancer.2015.08.006_bib0490","article-title":"The basal subtype to predict clinical benefit from neoadjuvant chemotherapy: final results from a phase II clinical trial of DDMVAC plus bevacizumab","volume":"33","author":"Siefker-Radtke","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0495","doi-asserted-by":"crossref","first-page":"23897","DOI":"10.3390\/ijms151223897","article-title":"The promise of novel molecular markers in bladder cancer","volume":"15","author":"Miremami","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0500","doi-asserted-by":"crossref","first-page":"21","DOI":"10.12703\/P5-21","article-title":"Urinary markers for bladder cancer","volume":"5","author":"Smith","year":"2013","journal-title":"F1000Prime Rep."},{"issue":"6","key":"10.1016\/j.semcancer.2015.08.006_bib0505","doi-asserted-by":"crossref","first-page":"e0124711","DOI":"10.1371\/journal.pone.0124711","article-title":"Somatic copy number abnormalities and mutations in PI3K\/AKT\/mTOR pathway have prognostic significance for overall survival in platinum treated locally advanced or metastatic urothelial tumors","volume":"10","author":"Bellmunt","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.semcancer.2015.08.006_bib0510","first-page":"2631","article-title":"Using mircoRNA profiling in urine samples to develop a non-invasive test for bladder cancer","volume":"133","author":"Mengual","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2015.08.006_bib0515","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.urology.2011.05.045","article-title":"Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma","volume":"78","author":"Flaig","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.semcancer.2015.08.006_bib0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2015.02.2951","article-title":"Circulating tumor cells as potential biomarkers in bladder cancer","author":"Alva","year":"2015","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.semcancer.2015.08.006_bib0525","first-page":"35","article-title":"Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer","volume":"8","author":"Utting","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.semcancer.2015.08.006_bib0530","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00120-014-3655-5","article-title":"Detection of cell-free lncRNA in serum of cancer patients","volume":"54","author":"Kohls","year":"2015","journal-title":"Urologe A."},{"issue":"4","key":"10.1016\/j.semcancer.2015.08.006_bib0535","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/10408363.2014.914888","article-title":"Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies","volume":"51","author":"Ralla","year":"2014","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"4","key":"10.1016\/j.semcancer.2015.08.006_bib0540","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.urolonc.2010.03.004","article-title":"Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies","volume":"30","author":"Ellinger","year":"2012","journal-title":"Urol. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2015.08.006_bib0545","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0302-2838(02)00126-4","article-title":"DNA alterations in body fluids as molecular tumor markers for urological malignancies","volume":"41","author":"Goessl","year":"2002","journal-title":"Eur. Urol."},{"issue":"19","key":"10.1016\/j.semcancer.2015.08.006_bib0550","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1056\/NEJM200311063491928","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.semcancer.2015.08.006_bib0555","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial","volume":"29","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2015.08.006_bib0560","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.urolonc.2013.10.021","article-title":"Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum","volume":"32","author":"Dinney","year":"2014","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0565","doi-asserted-by":"crossref","first-page":"13086","DOI":"10.1073\/pnas.0610292104","article-title":"A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery","volume":"104","author":"Lee","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0570","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1593\/neo.101214","article-title":"Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anti-cancer agents","volume":"13","author":"Smith","year":"2011","journal-title":"Neoplasia"},{"issue":"10","key":"10.1016\/j.semcancer.2015.08.006_bib0575","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov."},{"issue":"Suppl.","key":"10.1016\/j.semcancer.2015.08.006_bib0580","article-title":"Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer","volume":"33","author":"Wong","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0585","article-title":"ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy","author":"Groenendijk","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0590","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1158\/1078-0432.CCR-07-1593","article-title":"Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cell","volume":"14","author":"Black","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0595","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.juro.2006.03.072","article-title":"Schedule dependent efficacy of gefitinib and doxetacel for bladder cancer","volume":"176","author":"Kassouf","year":"2006","journal-title":"J. Urol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0600","doi-asserted-by":"crossref","first-page":"e30206","DOI":"10.1371\/journal.pone.0030206","article-title":"p63 expression defines a lethal subset of muscle-invasive bladder cancers","volume":"7","author":"Choi","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.semcancer.2015.08.006_bib0605","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2012.41.9572","article-title":"Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma","volume":"30","author":"Wong","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0610","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1021\/jm300207s","article-title":"Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein","volume":"55","author":"Debnath","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0615","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1158\/1078-0432.CCR-09-1650","article-title":"Inhibiting the hypoxia response for cancer therapy: the new kid on the block","volume":"15","author":"Koh","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0620","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","article-title":"Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial","volume":"16","author":"Carthon","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2015.08.006_bib0625","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1158\/1078-0432.CCR-08-0731","article-title":"T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival","volume":"14","author":"Boorjian","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.semcancer.2015.08.006_bib0630","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","article-title":"Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers","volume":"56","author":"Nakanishi","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"10.1016\/j.semcancer.2015.08.006_bib0635","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"issue":"7528","key":"10.1016\/j.semcancer.2015.08.006_bib0640","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2015.08.006_bib0645","first-page":"69","article-title":"Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer","volume":"29A","author":"Lipponen","year":"1992","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.semcancer.2015.08.006_bib0650","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1073\/pnas.0611618104","article-title":"CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma","volume":"104","author":"Sharma","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.semcancer.2015.08.006_bib0655","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.urolonc.2010.08.009","article-title":"Prognostic relevance of preoperative circulating CD8-positive lymphocytes in the urinary bladder recurrence of urothelial carcinoma","volume":"30","author":"Lin","year":"2012","journal-title":"Urol. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2015.08.006_bib0660","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3325\/cmj.2012.53.598","article-title":"The association between the recurrence of solitary non-muscle invasive bladder cancer and tumor infiltrating lymphocytes","volume":"53","author":"Krpina","year":"2012","journal-title":"Croat. Med. J."},{"issue":"Suppl.","key":"10.1016\/j.semcancer.2015.08.006_bib0665","article-title":"A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC)","volume":"33","author":"Petrylak","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"7528","key":"10.1016\/j.semcancer.2015.08.006_bib0670","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"Suppl.","key":"10.1016\/j.semcancer.2015.08.006_bib0675","article-title":"Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012","volume":"33","author":"Plimack","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2015.08.006_bib0680","doi-asserted-by":"crossref","first-page":"e1001216","DOI":"10.1371\/journal.pmed.1001216","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration","volume":"9","author":"Altman","year":"2012","journal-title":"PLoS Med."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X15000693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X15000693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T22:53:41Z","timestamp":1537397621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X15000693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":68,"alternative-id":["S1044579X15000693"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2015.08.006","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2015.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}